Tagged with B

Korea The nation of South Korea has overtaken many of its regional counterparts to boast a highly impressive biosimilars pipeline. Here, key stakeholders in Korean biologics and biosimilars explain how.   Once we chose to specialise in biosimilars, there was no room to survive if we failed with the few projects…

Korea ISU Abxis is a biotech company founded in 2001 with a focus on orphan drugs and rare disease. Part of the ISU chaebol, ISU Abxis has leveraged its parent company’s long-standing expertise in chemicals.   We have penetrated the Korean market already, and have received approval in 12 overseas emerging…

Opinion Eurasia Group’s Aditya Bhattacharji and Sarah Hassan identify and unpack the top three political and policy issues that multinational pharmaceutical firms are currently focusing on.   Issue One: The Global Economy Over the past month, one theme stood out at both the central bankers’ confab in Jackson Hole, Wyoming and…

USA Jennifer Hawks Bland of NewYorkBIO, the premier trade association for the life sciences in New York State, discusses the association’s diverse list of members, the services it provides them, and how New York is building a bio-ecosystem to rival those of Boston and California.   We have the unique ability…

Taiwan Jenny Chao and Aries Chang of BiotechTS, introduce the company as a leading one-stop-service provider for laboratory testing and explain its current transition from the food and safety space to being focused on biomedical and pharmaceutical testing.   Precision medicine is absolutely a growing trend in Taiwan where we see…

Taiwan Polly Lin, CEO of Guzip Biomarkers, discusses Guzip’s work in epigenetics and the role of DNA methylation in treating endometrial cancer. She highlights the benefits of MPap for women’s health and gives an overall assessment of Taiwan’s biotech ecosystem.   Taiwan’s advantages lie in our science, technology and innovation performance…

Cannabis PharmaBoardroom’s new InFocus section examines the fast-growing and lucrative global medical cannabis market, touching on investment opportunities, regulatory hurdles, regional hotspots and more.   With cannabis and cannabinoid treatments increasingly accepted as legitimate and effective medicines for a wide variety of conditions from chronic pain to mental disorders and even…

Taiwan Steve Profit, general manager of Novo Nordisk Taiwan, shares a newcomers’ perspective as a recent transplant to the market from the company’s global office in Denmark. Profit goes on to share his mission to fulfil CEO Lars Fruergaard Jørgensen’s strategy of expanding beyond being a leader of diabetes at the…

Puerto Rico After climbing through the ranks from sales representative to leading business units at Eli Lilly Canada, François Gilbert took the reins of Eli Lilly’s Puerto Rican affiliate last year. Among other things, he shares the reasons why Eli Lilly invests in strong commercial capabilities and clinical operations on the island,…

China Dr Li Shuai of pain- and CNS-focused Chinese biotech SIMR outlines the history of the company, the unmet medical needs it is seeking to address, its partnership strategy, and the complexities of attracting and retaining talent in the highly competitive Chinese market.   In 2014, my first angel investor actually…

Taiwan Francis Hong, chairman of Taiwan Medical and Biotech Industry Association (TMBIA), takes a moment during the 2019 Medical Taiwan and Taiwan Medical Components & Manufacturing Expo (MCMEX) in Taipei to share the mission of the Association, key issues being faced by its members, and an overview of Taiwan’s medical device landscape…

Sweden Having more than 20 years’ experience in the beverage industry, Isabelle Ducellier was appointed as the CEO of Swedish probiotics company BioGaia in November 2018. Here, Ducellier highlights her goal of moving the company into the B2B/B2C sector, regulatory obstacles for clinically proven probiotics and BioGaia’s long term strategy.  …